Articles Tagged With:
-
What Are Period Pills?
In this national survey of almost 7,000 people aged 15 to 49 years who were assigned female sex at birth, conducted between December 2021 and January 2022, one-quarter of participants (24%; 95% confidence interval [CI], 22%, 25%) stated that they would personally use period pills and about half of the respondents (52%; 95% CI, 50%, 53%) were in favor of the availability of period pills.
-
Intrauterine Hemorrhage-Control Devices for Postpartum Hemorrhage
This multicenter, prospective, observational study comparing intrauterine balloon tamponade vs. vacuum-induced devices for postpartum hemorrhage demonstrated no difference in blood loss after device placement (median quantitative blood loss, 194 mL balloon vs. 240 mL vacuum; P = 0.40), need for blood transfusion (59.7% balloon vs. 50.0% vacuum; P = 0.08), need for more than three units of packed red blood cells (27.0% balloon vs. 24.9% vacuum; P = 0.53), or device failure (7.7% balloon vs. 8.5% vacuum; P = 0.70).
-
Maternal Deaths, Illness Rise in Some States as Policy Changes Affect Reproductive Care Access
New research shows that more pregnancy-capable people in the United States could have difficulty accessing contraceptives. Also, maternal deaths and morbidity are rising and could continue to rise because of additional policy changes.
-
OB/GYNs Can Help Patients Struggling with Mental Health Issues Related to Dobbs
OB/GYNs and reproductive healthcare providers can help young women cope with mental stress by providing support.
-
Research Shows Providers Experiencing Distress Post-Dobbs Decision
Researchers conducted in-depth interviews with clinicians — both in states with abortion bans and those without bans — about how changes in pregnancy care because of the Dobbs decision affected them.
-
Potential Contraceptives, New Copper IUD May Offer More Non-Hormonal Options
Some scientists have focused on finding a nonhormonal-based contraception option that would be effective and acceptable to people who want to stay away from hormones and their side effects.
-
Relias Media is Now Clinician.com: What You Need to Know
As of June 25, Relias Media is officially rebranding as Clinician.com. This change marks an exciting new chapter in how we serve healthcare professionals — but rest assured, everything you rely on today will remain the same.
-
STEMI Watch 2025 Is Here!
Written with Mission: Lifeline® hospitals in mind, STEMI Watch 2025: Clinical Excellence in Prevention, Management, and Intervention provides physicians and staff with a concise and practical update on ST-segment elevation myocardial infarction (STEMI). In the ninth edition of this series, you'll gain valuable STEMI CME/CE while reviewing clinically relevant recommendations to improve consistency of cardiac care for patients.
-
Pediatric Tachycardia?
The electrocardiogram in the figure is from a previously healthy 15-year-old boy who reports palpitations and dizziness over the past two weeks. How would you interpret this tachycardia?
-
Avutometinib Capsules and Defactinib Tablets (Avmapki Fakzynja CO-PACK)
The U.S. Food and Drug Administration has granted accelerated approval for a combination of two kinase inhibitors, avutometinib and defactinib, for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, including a platinum-based regimen.